Vitiligo is a skin condition that affects up to 1.11% of the US population, causing loss of skin color and creating white patches on the skin. It can be especially upsetting when it affects the face, where it's more noticeable. Until recently, treatment options for vitiligo were limited to off-label drugs and therapies, but a new drug called Opzelura® has changed that.

Opzelura® is a cream that works by blocking certain proteins in the body that contribute to inflammation and the destruction of melanocytes, the cells responsible for skin pigmentation. By blocking these proteins, the drug helps to protect and preserve the melanocytes, allowing the skin to regain its natural color.

The European Commission has just approved Opzelura® for the treatment of non-segmental vitiligo in adults and adolescents with facial involvement. The EC decision follows the positive opinion received from the European Medicines Agency’s Committee earlier this year and is applicable to all 27 European Union Member States, Iceland, Norway and Liechtenstein.

Opzelura® was previously approved by the U.S. Food and Drug Administration (FDA) for the same indication, and now its approval in Europe is an important milestone in the effort to provide better care for individuals with vitiligo. This new treatment can be life-changing for those who have been struggling with this condition, helping them feel more confident and comfortable in their own skin.

INCYTE is the frontrunner among three dozen biotech companies developing vitiligo drugs, trailed by Pfizer with a drug candidate in Phase III clinical trials. Dig into exclusive report Vitiligo Drug Pipeline Analysis and Market Insights for more details.